Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients
Haematologica, 2002 - haematologica.org
BACKGROUND AND OBJECTIVES: The majority of cancer patients suffer from chronic
anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages …
anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages …
[PDF][PDF] Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients
Y BEGUIN - haematologica, 2002 - paulogentil.com
Trends in Hematology/Oncology review haematologica2002; 87: 1209-1221 http://www.
haematologica. org/2002_11/1209. htm therapy. 8 However, the chronic anemia that is so …
haematologica. org/2002_11/1209. htm therapy. 8 However, the chronic anemia that is so …
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.
Y Beguin - Haematologica, 2002 - orbi.uliege.be
BACKGROUND AND OBJECTIVES: The majority of cancer patients suffer from chronic
anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages …
anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages …
Erythropoietin and platelet production.
Y Beguin - Haematologica, 1999 - europepmc.org
Erythropoietin (Epo) is the primary growth factor for the red cell lineage but treatment with
recombinant human Epo (rHuEpo) has been shown to increase platelet counts. In several …
recombinant human Epo (rHuEpo) has been shown to increase platelet counts. In several …
[引用][C] Erythropoietin and platelet production
Y BEGUIN - Haematologica-Journal of hematology, 1999 - pascal-francis.inist.fr
Erythropoietin and platelet production CNRS Inist Pascal-Francis CNRS Pascal and Francis
Bibliographic Databases Simple search Advanced search Search by classification Search …
Bibliographic Databases Simple search Advanced search Search by classification Search …
Erythropoietin and platelet production
Y Beguin - Haematologica, 1999 - haematologica.org
BACKGROUND AND OBJECTIVE: Erythropoietin (Epo) is the primary growth factor for the
red cell lineage but treatment with recombinant human Epo (rHuEpo) has been shown to …
red cell lineage but treatment with recombinant human Epo (rHuEpo) has been shown to …
Erythropoietin and platelet production
Y Beguin - Haematologica, 1999 - pubmed.ncbi.nlm.nih.gov
Background and objective Erythropoietin (Epo) is the primary growth factor for the red cell
lineage but treatment with recombinant human Epo (rHuEpo) has been shown to increase …
lineage but treatment with recombinant human Epo (rHuEpo) has been shown to increase …
[引用][C] Erythropoietin and platelet production
Y BEGUIN - Haematologica, 1999 - cir.nii.ac.jp
Erythropoietin and platelet production | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
Erythropoietin and platelet production.
Y Beguin - Haematologica, 1999 - orbi.uliege.be
BACKGROUND AND OBJECTIVE: Erythropoietin (Epo) is the primary growth factor for the
red cell lineage but treatment with recombinant human Epo (rHuEpo) has been shown to …
red cell lineage but treatment with recombinant human Epo (rHuEpo) has been shown to …
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients
Y Beguin - Haematologica, 2002 - pubmed.ncbi.nlm.nih.gov
Background and objectives The majority of cancer patients suffer from chronic anemia.
While recombinant human erythropoietin (rHuEPO) offers many of the advantages of blood …
While recombinant human erythropoietin (rHuEPO) offers many of the advantages of blood …